TORONTO--(BUSINESS WIRE)--Ostia Sciences Inc., a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, has successfully raised over CAD $1 million in its seed round and secured full intellectual property (IP) transfer from the university. “With full IP ownership and new funding, we’re ready to accelerate development of our SALI-10 probiotic,” added CSO Dr.

多伦多--（商业新闻短讯）--多伦多大学专门从事口腔和呼吸道微生物组解决方案的分支机构Ostia Sciences Inc.在种子期成功筹集了100多万加元，并获得了该大学的全部知识产权转让。CSO博士补充道：“拥有完全的知识产权和新的资金，我们准备加速SALI-10益生菌的开发。”。

Michael Glogauer. The company aims to close the round with an additional $700,000 by December 2024..

迈克尔·格洛高尔。该公司计划在2024年12月前追加70万美元。

This funding will support the development of its SALI-10 probiotic, based on its phosphorylated lantibiotic technology, which is ready for clinical trials targeting respiratory and oral diseases in early 2025. These milestones will enable Ostia to partner with leading contract development and manufacturing organizations (CDMOs) to scale production..

这笔资金将支持其基于磷酸化羊毛硫菌技术的SALI-10益生菌的开发，该技术已准备好在2025年初进行针对呼吸道和口腔疾病的临床试验。这些里程碑将使Ostia能够与领先的合同开发和制造组织（CDMO）合作，以扩大生产规模。

With full IP ownership, Ostia can independently advance research and development, solidifying its position as a leader in the emerging “Bugs to Drugs” biotherapeutic field. The investment will further research, clinical trials, and manufacturing as Ostia brings its innovative therapies to market.

拥有完全的知识产权，Ostia可以独立推进研究和开发，巩固其在新兴的“细菌到药物”生物治疗领域的领先地位。随着Ostia将其创新疗法推向市场，该投资将进一步研究，临床试验和制造。

“Our new phosphorylated lantibiotic technology offers targeted antimicrobial and pro-immune benefits that are unprecedented in the market,” said CEO Dr. Abdelahhad Barbour. “This seed round will allow us to expand our discovery pipeline, and with our first prototype ready for clinical trials, we are well-positioned to drive our vision forward.”.

首席执行官Abdelahad Barbour博士说：“我们新的磷酸化羊毛硫抗生素技术提供了市场上前所未有的有针对性的抗菌和免疫益处。”。“这一轮种子将使我们能够扩大我们的发现渠道，随着我们的第一个原型准备好进行临床试验，我们已经做好了推动我们的愿景向前发展的准备。”。

For more information about Ostia's funding and structure, please visit our company profile through our exempt market dealer (EMD), Equivesto.

有关Ostia资金和结构的更多信息，请通过我们的豁免市场交易商（EMD）Equivesto访问我们的公司简介。

About Ostia Sciences Inc.

关于Ostia Sciences Inc。

Ostia Sciences Inc. is a Toronto-based biotech company specializing in the development of innovative oral probiotics and biotherapeutics. Through cutting-edge research and a commitment to microbiome science, Ostia Sciences is dedicated to improving global health outcomes with impactful biotherapeutic solutions..

Ostia Sciences Inc.是一家总部位于多伦多的生物技术公司，专门从事创新口腔益生菌和生物治疗药物的开发。通过尖端研究和对微生物组科学的承诺，Ostia Sciences致力于通过有效的生物治疗解决方案改善全球健康结果。